Breaking News, Collaborations & Alliances

Lonza, Akouos and MEE Enter Gene Therapy Pact

Lonza and MEE grant Akouos exclusive licenses to proprietary ancestral AAV vectors for all hearing and balance disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza, Massachusetts Eye and Ear (MEE) and Akouos, a new biotechnology company focused on restoring and preserving hearing, unveiled their strategic license agreements for exclusive rights to the ancestral adeno-associated viral vectors (Anc-AAV) gene therapy platform for all hearing and balance disorders. The agreement with Akouos is designed to accelerate AAV gene therapy for hearing and balance disorder. It builds on the existing Anc-AAV partnership between MEE and Lonza, and brings togeth...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters